BMS 135
Alternative Names: BMS-135Latest Information Update: 08 Jun 2023
Price :
$50 *
At a glance
- Originator Bristol-Myers Squibb
- Class Antineoplastics; Small molecules
- Mechanism of Action Casein kinase II inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia; Precursor B-cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 14 Apr 2023 Preclinical trials in Acute myeloid leukaemia in USA (PO)
- 14 Apr 2023 Pharmacodynamics and safety data from a preclinical study in Acute myeloid leukemia presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 26 Oct 2022 Preclinical trials in Precursor B-cell lymphoblastic leukaemia-lymphoma in USA (Intraperitoneal)